Sophie Laborde
Researcher
Data updated
Papers
Trials
Research Footprint
Sophie Laborde appears in 5 tracked papers (2024–2026), most studied alongside DMT, Placebo and Psilocybin, across Healthy Volunteers, Depressive Disorders and Anxiety Disorders.
Most-cited paper: Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression (27 citations).
Frequent co-authors: Fernanda Palhano-Fontes, Isabel Wießner and Handersson Barros.
Background & Research
Sophie Laborde is a researcher associated with clinical psychedelic studies in Brazil, including work on inhaled and vaporized N,N-dimethyltryptamine (DMT). Her publications show involvement in early-phase safety studies and depression-focused trials at the Federal University of Rio Grande do Norte / Center for Advanced Medical Psychedelics (CAMP).
Key Impact
She coauthored multiple clinical DMT papers spanning safety, tolerability, and antidepressant effects, indicating a key role in a notable psychedelic clinical research program.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →